TScan Therapeutics (TCRX) Operating Expenses (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Operating Expenses of $30.1 million for Q1 2026, down 21.6% year-over-year from $38.4 million in Q1 2025, and up 13.99% quarter-over-quarter from $26.4 million in Q4 2025.
TScan Therapeutics (TCRX) Operating Expenses (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Operating Expenses for 7 consecutive years, with $30.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 21.6% year-over-year to $30.1 million; the TTM figure through Mar 2026 stood at $137.8 million (down 4.36% YoY), while the FY2025 annual figure was $146.1 million, up 6.18% from the prior year.
- Operating Expenses grew to $30.1 million in Q1 2026 per TCRX's latest filing, from $26.4 million in the prior quarter.
- Across five years, Operating Expenses topped out at $41.7 million in Q2 2025 and bottomed at $19.2 million in Q1 2022.
- Historically, Operating Expenses has averaged $29.9 million across 5 years, with a median of $29.5 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Expenses surged 92.9% — and 2025, when it decreased 29.3%.
- TScan Therapeutics' Operating Expenses stood at $21.7 million in 2022, then soared by 31.38% to $28.6 million in 2023, then soared by 30.84% to $37.4 million in 2024, then fell by 29.3% to $26.4 million in 2025, then gained by 13.99% to $30.1 million in 2026.
- Business Quant data shows TCRX's Operating Expenses at $30.1 million in Q1 2026, $26.4 million in Q4 2025, and $39.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | TScan Therapeutics | 101.63 Mn | 101.63 Mn | - | 31.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.54 Mn |
| Mar 31, 2026 | 30.12 Mn |
| Dec 31, 2025 | 26.43 Mn |
| Sep 30, 2025 | 39.56 Mn |
| Jun 30, 2025 | 41.73 Mn |
| Mar 31, 2025 | 38.42 Mn |
| Dec 31, 2024 | 37.38 Mn |
| Sep 30, 2024 | 33.67 Mn |
| Jun 30, 2024 | 34.65 Mn |
| Mar 31, 2024 | 31.94 Mn |
| Dec 31, 2023 | 28.57 Mn |
| Sep 30, 2023 | 28.64 Mn |
| Jun 30, 2023 | 27.76 Mn |
| Mar 31, 2023 | 29.55 Mn |
| Dec 31, 2022 | 21.74 Mn |
| Sep 30, 2022 | 19.94 Mn |
| Jun 30, 2022 | 19.30 Mn |
| Mar 31, 2022 | 19.18 Mn |
| Dec 31, 2021 | 17.06 Mn |
| Sep 30, 2021 | 18.25 Mn |